Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy


MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients of MaxCyte’s Phase I clinical trial (NCT03608618) with the next higher cell dose of MCY-M11. The dose-escalation trial is evaluating the safety and tolerability, as well as preliminary efficacy, of MCY-M11 administered intraperitoneally across a series of ascending dose-level cohorts.

What is MCY-M11: MCY-M11 is a mesothelin-targeting chimeric antigen receptor (CAR) therapy. It is a wholly-owned, non-viral mRNA-based cell therapy candidate from MaxCyte’s CARMA platform. The therapy is currently being tested in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

What were the results in the first two cohorts: According to the company, in the first two cohorts, the infusion of MCY-M11 has been well-tolerated in all patients treated. No dose-limiting toxicities, infusion-related adverse events, on-target or off-target toxicities, or other unwanted events were observed.

Check out the complete detail, here.

For additional details on KOL opinion about the cell therapies market, check the blog Market report for Cell Therapy.

One Comment